Compare Abeona Therapeutics Inc (ABEO) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Caesars Entertainment Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Caesars Entertainment Inc trades at $29.85 (market cap $6.18B). The key difference: Caesars Entertainment Inc is far larger — about 16.6× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | CZR | |
|---|---|---|
Market Cap | $373.32M | $6.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $31.51 |
52-Week Low | $4.17 | $18.14 |
Enterprise Value | $228.22M | $30.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CZR trades at $30.35, down 0.13% with a neutral technical stance despite bullish moving averages. The company reported a net loss of $502M in 2025 with negative margins, though revenue grew to $11.49B. Valuation ratios like P/E of 10.42 and P/S of 0.54 appear attractive, but recent earnings misses and a pending acquisition by Fertitta Entertainment at $31.00 per share dominate sentiment. Cash flow trends show improving operational performance with net cash flow narrowing to -$32M in 2025.
The outlook is mixed: the acquisition offers a near-term floor, but operational losses and high debt of $12.03B pose risks. Analysts are cautious with 63.3% hold ratings, citing competitive pressures and integration uncertainties. Investors should weigh the buyout premium against fundamental weaknesses in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
